Skip to content

People

Diego Miralles

CEO-Partner

Diego Miralles is a veteran pharmaceutical and biotech leader who joined Flagship Pioneering in 2020, as CEO-Partner and CEO of Laronde.

Diego was previously CEO of Vividion Therapeutics, Inc., a biotechnology company focused on the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. As CEO, he led a team that raised over $360 million in venture capital and two large partnerships with BMS/Celgene and Roche. Prior to this role, he was President of Adaptive Therapeutics, a division of Adaptive Biotechnologies focused on clinical therapeutic applications of TCR sequencing.

Diego also spent eleven years at Johnson & Johnson, where he most recently served as Global Head of Johnson & Johnson Innovation. Diego’s many achievements at J&J include leading Janssen’s Research and Early Development Unit in California and establishing the J&J Innovation Centers and Janssen/JLABS. Diego was also Vice President of Clinical Development at Tibotec, a J&J company, where he led a team that put six drugs in the clinic, ultimately garnering five approvals, including PREZISTA® and INTELENCE®. Earlier in his career, he served in R&D roles at Trimeris, Inc. and Triangle Pharmaceutical focusing on the development of antivirals. During that tenure, he worked on the clinical development of a total of eight compounds, two of which ultimately made it to the market: Fuzeon and Emtriva.

Diego began his academic career as an Assistant Professor at Duke University Medical Center, where he practiced as an HIV physician and conducted basic research in T cell development. He received an M.D. from Universidad de Buenos Aires, Argentina and conducted his residency at the Mayo Clinic in Rochester, Minn., and his fellowship in Infectious Diseases at New York Hospital-Cornell University Medical Center.